search icon
  • Print
  • ShareThis
  • Text Size
  • Antibiotic Development: The 10 x '20 Initiative

    Bringing New Antibiotics to Patients Who Need Them

    • Brianna slider

      Patient Story : Brianna Strand

      A woman from Washington with cystic fibrosis suffers years of worsening symptoms stemming from a skin infection.

      Born with Cystic Fibrosis (CF), Brianna Strand was used to being treated for the routine lung infections associated with the disease.


      Read Brianna's Story >>
    • Mary slider

      Patient Story : Mary Millard

      After contracting an antibiotic-resistant infection, a woman from North Carolina faces surgery as a final treatment option.

      "Mary is currently on the maximum dosage… and if it stops working, her last resort will be to have surgery."

      Read Mary's Story >>
    • Meredith slider

      Patient Story : Meredith Littlejohn

      A 19-year-old college hopeful and cancer survivor dies from an antibiotic-resistant infection.

      "During the procedure her blood oxygen levels dropped significantly and she went into septic shock."


      Read Meredith's Story >>
    • Braxe slider image

      Patient Story : Braxe R.

      A seemingly harmless ear infection turns into a life-threatening MRSA scare for a 2 ½ year old boy.

      "But my wife and I were fearful, knowing that with every failed attempt to cure the infection the situation became more critical."


      Read Braxe's Story >>

    The Problem:  Antibiotic-Resistant Bacteria

    Because of antibiotic resistance, many bacterial infections have become impossible to treat.  New antibiotics are desperately needed to save patients' lives, but few new drugs are in pharmaceutical companies' research and development (R&D) pipelines.  Low returns on investments and an unpredictable and often infeasible approval pathway at the U.S. Food and Drug Administration (FDA) have caused many companies to leave the antibiotics market.

    IDSA is working to counter this decline through the 10 x '20 Initiative (read our statement).  The initiative seeks a global commitment to create an antibiotic R&D enterprise powerful enough to produce 10 new systemic antibiotics by the year 2020.  This effort has the potential to save thousands of lives each year.  To achieve our goal, IDSA is working with a broad range of stakeholders in the United States and globally.  We need your help!

    Antibiotic Resistance and You


    Urge Congress to Support Antibiotic Research & Development


    Endorse the 10 x '20 Initiative

    Join other medical societies, public health organizations, and universities in endorsing the 10 x '20 initiative. See who else has joined us >>

    Frontline Image

    Stop Bad Bugs

    Take Action: Tell Congress to join efforts to combat antibiotic resistance and learn more about what you can do to stop bad bugs. Get Smart >>

    Share Your Story

    Share Your Story

    If you or a loved one have been devastated by an antibiotic resistant bacterial infection and you would like to share your story, please contact Diana Olson.

  • Statements and Reports (26)
    Agency Efforts (45)
    • 08/30/2018

      IDSA Comments to WHO IACG on AMR Discussion Papers and Input (PDF)

      IDSA submitted comments to the WHO Interagency Coordination Group on Antimicrobial Resistance, strongly supporting international efforts to advance comprehensive solutions to antimicrobial resistance, including stimulating research and development for new antibiotics and diagnostics, implementing stewardship and infection prevention programs, and strengthening surveillance.
    • 07/25/2018

      IDSA Comments to FDA Re Draft Guidance on LPAD (PDF)

      IDSA comments to FDA on the draft guidance Limited Population Pathway for Antibacterial and Antifungal Drugs.
    • 07/10/2018

      IDSA Comments to FDA and CMS on Antibiotic RD Incentives and Stewardship (PDF)

      IDSA comments to FDA and CMS on the urgent need to provide incentives for the research, development, and judicious use of antibiotics to address the threat of antimicrobial resistance.
    • 07/09/2018

      IDSA Comments to UN Interagency Coordination Group on AMR (PDF)

      IDSA comments to the United Nations Interagency Coordination Group (IACG) on Antimicrobial Resistance (AMR) to help inform its efforts to advance comprehensive solutions to AMR, including stimulation research and development for urgently needed new antibiotics and diagnostics, implementing infection prevention and stewardship programs, and strengthening surveillance.
    • 02/13/2018

      IDSA Introduction to HHS Secretary Azar on ID Priorities (PDF)

      IDSA congratulates new HHS Secretary Alex Azar on his appointment and highlights key issues facing patients and public health, including antimicrobial resistance, ID implications of the opioid epidemic, global health security, public health infrastructure and immunizations, research investments, and the ID physician workforce.
    Legislative Efforts (51)
    Background (37)
    Related Websites (4)
    FOAR (6)
    • Tenzin Lobsang Kunor

      Tenzin Lobsang Kunor Tenzin  Lobsang Kunor was in the last semester of college, had just been admitted to graduate school, and offered an assistantship connected to the program. Best of all, he recently started dating the love of his life. He felt happy, carefree, and enthusiastic about th

    • Simon Sparrow

      It seems unfathomable that a healthy, hearty and beautiful little boy could have been infected with a deadly bug and be gone in less than 24 hours. MRSA took my son swiftly. Now I have a window into what so many families experienced 50+ years ago: the death of a child caused by a bacterium or virus. It is ironic that the same advances in science that helped us live healthier and longer lives led to the creation of bacteria that no longer respond to antibiotics. As long as we do not treat antibiotics as a precious resource only to be used in the most extreme cases we will continue to have a false sense of security in medicine.
    • Roger Poser

      Dr. Gentry prescribed ciprofloxacin, which was temporarily holding the infection  at bay. Dr. Gentry suggested Zerbaxa®, a combination antibiotic therapy that was not FDA-approved to treat pseudomonas but had shown promising test results. Because Zerbaxa® is very difficult to obtain, Roger was put on a waiting list. Several weeks passed, and his infection became increasingly resistant to the ciprofloxacin. Finally, doctors obtained the Zerbaxa®. Within one day of treatment, Roger’s white blood cell count dropped dramatically and approached the normal range. Doctors 

       remained skeptical about Roger’s recovery as his infection could develop a resistance to Zerbaxa® as well. But his white blood cell count continued to improve, so Dr. Gentry tapered him off the Zerbaxa® to see if the infection would return. It did not, and Roger was able to go home, nearly four months after his initial surgery. He has recovered, with no signs of re-infection. Roger’s immune system was severely weakened after extended courses of antibiotics, and he has been briefly readmitted to the hospital several times for minor illnesses. But he recently overcame a cold on his own without being hospitalized.

    • Natalie

      Natalie’s unpredictable recurrences of her chronic MRSA and extremely burdensome regimen forced a revamping of her and her high school daughter’s lives. Three years ago she was unable to continue her non-profit consulting work and had to close her 25-year-old business. Her income has been drastically reduced and she now lives on disability and uses Medicare for health insurance. Because of another recurrence, she was unable to take her daughter on a long-planned summer vacation this year and because she was so ill, she had to rely on others to provide care for her daughter for about five weeks this summer.
    • Mary Millard

      Mary currently takes the maximum dosage of ciprofloxacin and if it stops working, her last resort will be to have surgery. Her doctors say surgery would have 50/50 chance of working due to complexity, after which she will be out of treatment options and would likely die. 

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site